Hepatitis delta virus (HDV) only exists in patients with hepatitis B virus (HBV) coinfection. In part 1 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on serologic testing for both HDV and HBV and steps to take in monitoring, treating, and reassessing HBV in patients coinfected with HDV. Presenters: Heiner Wedemeyer, MD Professor and Chairman Department of Gastroenterology, Hepatology, and Endocrinology Hannover Medical School Hannover, ...
Mar 10, 2022•21 min•Ep. 141
Episode 3 of this series features Anna Cristina L. dela Cruz, MD, in conversation with patient Melody Cheng about Melody’s decision to start hepatitis B virus (HBV) antiviral therapy during pregnancy. This podcast also discusses recommended approaches to preventing HBV transmission from mother to child, current recommendations on starting treatment for chronic HBV infection, and the issues around stopping treatment. Presenter: Anna Christina L. dela Cruz, MD Associate Professor Division of Diges...
Mar 07, 2022•11 min•Ep. 140
Treatment options for hepatitis delta virus (HDV) are lacking, but many exciting agents are under investigation. Hear Drs Nancy Reau and Stefan Zeuzem discuss their thoughts on up-and-coming agents for treating HDV, and explore what questions need answering to most effectively use currently available and emerging therapies, which include: Bulevirtide Interferon λ Lonafarnib Presenters: Nancy Reau, MD Professor of Medicine Chief , Section of Hepatology Associate Director , Solid Organ Transplanta...
Mar 03, 2022•17 min•Ep. 139
In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B. The conversation focuses on the stigma many patients experience following diagnosis and how access to treatment may reduce this. Presenter: Robert G. Gish, MD Professor of Medicine Loma Linda University Loma Linda, California Adjunct Professor of Medicine Nevada School of Me...
Feb 24, 2022•17 min•Ep. 137
In this episode, Drs Norah Terrault, MD, MPH, and Grace LH Wong, MD, share lessons learned in the care of patients with hepatitis B virus (HBV) in the COVID-19 era, including: HBV cascade of care before vs during the pandemic Innovative strategies to improve HBV diagnosis and linkage to care Lessons learned in telemedicine Elimination through vaccination Management of HBV and COVID-19 coinfection Management of elevated liver enzymes in COVID-19 Presenters: Norah Terrault, MD, MPH Professor of Me...
Feb 24, 2022•26 min•Ep. 136
In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses what is known about the SARS-CoV-2 omicron variant, including: Transmissibility and infectiousness Immune evasion Disease severity Risks of hospitalization and death Vaccine effectiveness 2- vs 3-dose vaccine effectiveness T-cell response Presenter: Sharon R. Lewin, AO, FRACP, PhD, FAHMS Director , The Peter Doherty Institute for Infection and Immunity Professor of Infectious Diseases University of Melbourne Consultant Infectious...
Feb 22, 2022•37 min•Ep. 135
In episode 6 of an ongoing series of sharing sessions between a physician and patient, Tarik Asselah, MD, PhD, and his patient, who is living with chronic hepatitis B (CHB), discuss: Importance and goals of hepatitis B virus (HBV) treatment, with a call for broader access to treatment worldwide Screening for HBV, especially given the frequency of asymptomatic disease HBV vaccination as a preventive measure Living a healthy life and maintaining hope while living with CHB Presenter: Tarik Asselah,...
Feb 18, 2022•11 min•Ep. 134
In this episode, Mark S. Sulkowski, MD, explores recommendations and data on treating HIV and hepatitis C virus (HCV) in patients who are coinfected. Listen as he gives his perspectives on: Prioritization of both HIV and HCV treatment Efficacy of HCV direct-acting antivirals in people with HIV American Association for the Study of Liver Diseases/Infectious Diseases Society of America recommendations for first-line HCV treatment in HIV/HCV coinfection International guidance on first-line antiretr...
Feb 16, 2022•18 min•Ep. 133
In this episode, Mark S. Sulkowski, MD, discusses his recommended approach for managing nonalcoholic steatohepatitis in patients with HIV, including recognizing nonalcoholic steatohepatitis, recommending lifestyle interventions, and considering pharmacologic approaches. Presenter: Mark S. Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Chief, Infectious Disease Johns Hopkins Bayview Medical Center Johns Hopkins University School of Medicine Baltimore, Maryland Conten...
Feb 15, 2022•7 min•Ep. 132
In this episode, Robert G. Gish, MD, and Pietro Lampertico, MD, PhD, share lessons learned in the care of patients coinfected with hepatitis B virus and hepatitis delta virus (HDV), including: Burden of HDV infection Chronic HDV infection and comorbidities Impact of COVID-19 on care of patients with chronic hepatitis B Screening for HDV and which assays to use Screening for viral hepatitis at a COVID-19 vaccination site Presenters: Robert G. Gish, MD, FAASLD, AGAF, FAST Professor of Medicine Lom...
Feb 11, 2022•30 min•Ep. 131
In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for antiretroviral therapy (ART) use in older patients with renal and hepatic impairment. European AIDS Clinical Society guideline screening recommendations for kidney disease in people with HIV Antiretroviral dose adjustment recommendations based on estimated glomerular filtration rate Data on the use of full-dose lamivudine with ren...
Feb 10, 2022•31 min•Ep. 130
In this episode, Jürgen K. Rockstroh, MD, and Giada Sebastiani, MD, discuss key strategies to appropriately screen for, identify, and manage nonalcoholic steatohepatitis in persons with HIV. They also answer pressing questions from healthcare professionals. Presenters: Jürgen K. Rockstroh, MD Professor of Medicine University Hospital Bonn Department of Medicine I Bonn, Germany Giada Sebastiani, MD Associate Professor of Medicine McGill University Health Centre Division of Gastroenterology and He...
Feb 09, 2022•38 min•Ep. 129
In this episode, Jürgen K. Rockstroh, MD, discusses his recommended approach for diagnosing nonalcoholic steatohepatitis in patients with HIV, the value of noninvasive diagnostic tests such as serum biomarkers and elastography, and how timely nonalcoholic fatty liver disease assessment and metabolic risk factor determination can result in early interventions. Presenter: Jürgen K. Rockstroh, MD Professor of Medicine University Hospital Bonn Department of Medicine I Bonn, Germany Content based on ...
Feb 03, 2022•6 min•Ep. 128
In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced. Listen as he gives his perspectives on: US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotyping US Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resis...
Feb 01, 2022•18 min•Ep. 127
In this episode, Rageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIV, and Solange L. Baptiste, ScM, discuss the burden of HIV among BIPOC and migrant communities and key strategies to reduce racial disparities in HIV care globally: Disproportionate impact of HIV among BIPOC communities and migrant populations globally Barriers to HIV testing, prevention, and treatment services among BIPOC communities and migrant populations Strategies to overcome health system–based and provider-based ba...
Jan 26, 2022•39 min•Ep. 126
In this episode, John D. Baxter, MD, explores recommendations and data on choosing antiretroviral therapy with transmitted drug resistance. Listen as he gives his perspectives on: Initial response to antiretroviral therapy during primary HIV infection with baseline resistance Data from the START study on treatment-naive patients with transmitted drug resistance by region and drug class Recommendations from the US Department of Health and Human Services and International AIDS Society–USA guidelin...
Jan 25, 2022•18 min•Ep. 124
The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including: Direct-acting, small-molecule antiviral agents such as molnupiravir, nirmatrelvir + ritonavir, and remdesivir Monoc...
Jan 25, 2022•42 min•Ep. 125
In this episode, Samantha V. Hill, MD, MPH, and David Malebranche, MD, MPH, examine key facilitators to tackling racial inequities in HIV care, including: Barriers to HIV testing, prevention, and treatment services in BIPOC communities and migrant populations Facilitators to HIV testing, prevention, and treatment services in BIPOC communities and migrant populations Strategies to overcome health system–based and healthcare professional–based barriers to engagement with HIV care Samantha V. Hill,...
Jan 12, 2022•51 min•Ep. 123
In this episode from the series “Key Decisions in HIV Care,” Daria Podlekareva, MD, PhD, and Mark S. Sulkowski, MD, discuss important considerations for ART use in patients with coinfections, including: DHHS testing and treatment recommendations for HBV in patients with HIV Data suggesting that tenofovir alone may not suppress HBV in all PWH Data from NA-ACCORD showing that incomplete HBV DNA suppression is associated with HCC in patients with HIV/HBV Data for the use of entecavir as an add-on t...
Jan 10, 2022•39 min•Ep. 122
In this episode, Karen Ha, MD, explores recommendations and data on the role of PIs in current practice. Listen as she gives her perspectives on: DHHS guideline recommendations on the use of PI-based ART Data from the DIAMOND study on the use of boosted DRV for rapid initiation Data from the EARNEST and NADIA studies on the use of PI-based ART with NRTI resistance Considerations for the use of PIs in patients with cardiovascular risk, including data from the D:A:D study Key drug–drug interaction...
Jan 06, 2022•8 min•Ep. 121
In this episode, Renslow Sherer, MD, discusses key data on COVID-19 oral antiviral agents—molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir—for nonhospitalized adults with mild to moderate COVID-19, including: EPIC-HR study of nirmatrelvir (PF-07321332) plus ritonavir Safety data Efficacy data MOVe-OUT study of molnupiravir Safety data Efficacy data Roles in treatment of COVID-19 Timing of treatment Presenter: Renslow Sherer, MD Director , International HIV Training Center Professor of ...
Jan 06, 2022•37 min•Ep. 119
In this episode, Karen Ha, MD, explores recommendations and data on the role of NNRTIs in current practice. Listen as she gives her perspectives on: DHHS guideline recommendations on the use of NNRTI-based ART Weight gain data from the ADVANCE study, DRIVE-AHEAD, DRIVE-FORWARD, DRIVE-SHIFT, and a multivariate analysis of weight gain on ART Key food effects and drug–drug interaction considerations with the use of NNRTIs Presenter: Karen Ha, MD Assistant Professor of Medicine Division of Infectiou...
Jan 06, 2022•9 min•Ep. 120
In this episode, Christian R. Pollard provides his perspectives as an individual taking daily oral HIV PrEP, including factors he considered in the decision to use PrEP, his experience with taking PrEP (daily pills and periodic laboratory testing), and his thoughts on what opportunities future PrEP options may offer. Presenter: Christian R. Pollard Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc. Link to full program: https://bit.ly/...
Jan 03, 2022•8 min•Ep. 118
In this episode from the series “Key Decisions in HIV Care,” W. David Hardy, MD, and Josep M. Llibre, MD, PhD, discuss important considerations for ART use in the context of virologic failure and resistance, including: A discussion of the definitions of the following: highly treatment experienced, complex ART, multidrug-resistant HIV, and limited treatment options The scope of the problem, including data from the CNICS cohort DHHS and EACS guideline recommendations on the management of virologic...
Dec 29, 2021•43 min•Ep. 117
Hear insights from 3 faculty experts as they present emerging data and guidelines and engage in discussion on patient-centered ART selection for people with HIV. Topics include assessing treatment options; individualizing ART for women of childbearing potential and during pregnancy, patients with OIs, and during the COVID-19 pandemic; and new data on investigational ART strategies. Learn how to: Apply the results of recent clinical studies and evolving treatment guidelines on the timing and choi...
Dec 21, 2021•1 hr 10 min•Ep. 116
In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including: DHHS, EACS, IAS, and WHO recommendations for first-line ART Virologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National Survey Polypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug int...
Dec 21, 2021•42 min•Ep. 115
Hepatitis delta is the most severe form of viral hepatitis, and many patients remain undiagnosed. In this episode, Maria Buti, MD, and Robert G. Gish, MD, discuss the prevalence and severity of hepatitis delta. Hear their personal experiences from the clinic and their call to action for universal screening of patients with hepatitis B for coinfection with hepatitis delta. Presenters: Maria Buti, MD Professor of Medicine Hospital Universitario Vall d'Hebron Barcelona, Spain Robert G. Gish, MD Pro...
Dec 20, 2021•22 min•Ep. 114
In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on patient specific factors associated with LA CAB plus RPV failure. Listen as she gives her perspectives on: LA CAB plus RPV pharmacokinetic data DHHS guideline recommendations on which patients can be considered for LA CAB plus RPV Data from the ATLAS, FLAIR, and ATLAS-2M studies on patients with virologic failure and the factors that may have contributed Presenter: Milena Murray, PharmD, MSc, BCIDP, ...
Dec 16, 2021•12 min•Ep. 113
In this episode, Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA), and Ming-Lung Yu, MD, PhD, discuss key racial inequities of care that lead to undertreatment for migrant populations and other racial minorities globally with or at risk for hepatitis B. In addition, they discuss plans to improve engagement across the care continuum and strategies to combat implicit racial biases that affect optimal HBV care. Topics include: Differences in the burden of HBV globally Suboptimal engagement of HBV car...
Dec 15, 2021•42 min•Ep. 112
In this episode, Dalilah Restrepo, MD, discusses barriers to shingles vaccination and strategies to increase routine vaccine uptake in the COVID-19 era. Using the latest data and expert guidance, this podcast covers topics such as: Shingles disease burden and increasing incidence over time Decline in shingles vaccination rates in the COVID-19 era National Vaccine Advisory Committee standards of care CDC guidance catching up after RZV dosing delays Strategies to increase shingles vaccine uptake P...
Dec 14, 2021•18 min•Ep. 111
